Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at

Investment analysts at began coverage on shares of Trevena (NASDAQ:TRVNGet Free Report) in a note issued to investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright lowered their target price on Trevena from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, May 16th.

Check Out Our Latest Research Report on TRVN

Trevena Price Performance

Shares of NASDAQ TRVN opened at $0.22 on Thursday. Trevena has a one year low of $0.19 and a one year high of $1.12. The business’s 50-day moving average price is $0.35 and its two-hundred day moving average price is $0.48. The company has a market capitalization of $4.12 million, a P/E ratio of -0.08 and a beta of 1.05.

Trevena (NASDAQ:TRVNGet Free Report) last posted its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.01. The company had revenue of $0.02 million during the quarter. On average, equities analysts anticipate that Trevena will post -1.29 EPS for the current year.

Hedge Funds Weigh In On Trevena

An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC bought a new position in shares of Trevena, Inc. (NASDAQ:TRVNFree Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned approximately 4.61% of Trevena as of its most recent SEC filing. Hedge funds and other institutional investors own 13.56% of the company’s stock.

Trevena Company Profile

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Featured Articles

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with's FREE daily email newsletter.